Brain stimulation device cleared for ADHD in the US is overall safe but ineffective

A large multicentre clinical trial led by King’s College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms.

2026-01-16

(Press-News.org) A large multicentre clinical trial led by King’s College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms.

The device – which uses an approach called trigeminal nerve stimulation (TNS) - was cleared for use by the US Food and Drugs Administration (FDA) to treat ADHD in 2019 based on a small study. These new findings from a larger multicentre trial, published in the journal Nature Medicine, suggest authorities should revisit the original evidence that supported the FDA clearance. Notably, TNS is currently not recommended for use in the UK by NICE (National Institute for Health and Care Excellence) guidelines.

The trial was run in collaboration with University of Southampton and funded by the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the National Institute for Health and Care Research (NIHR) and the UKRI Medical Research Council (MRC), with further support from the NIHR Maudsley Biomedical Research Centre.

Attention-Deficit/Hyperactivity Disorder (ADHD) affects five to eight per cent of school-age children worldwide and is associated with age-inappropriate problems with attention and/or hyperactivity and impulsivity that can impair everyday functioning.

Stimulant medications improve symptoms in 70 per cent of those who take them in the short term but there is less evidence of their long-term effects.

To provide an alternative to medication researchers have developed and trialled approaches that use non-invasive stimulation of the brain, working on the regions that have been identified as influential in ADHD.

One of these approaches involves stimulating the trigeminal nerve (TNS), targeting a branch of this facial nerve which is thought to activate the brainstem and from there other brain regions that may be relevant to ADHD, in particular the locus coeruleus, which plays a role in arousal which is typically diminished in people with ADHD. TNS is thought to stimulate other brain regions associated with attention such as frontal and thalamic areas via the brainstem in a bottom-up manner.

A previous small trial in the US with 62 children diagnosed with ADHD has shown that when TNS is applied every night for eight hours for one month it is effective in reducing symptoms – this research led to its clearance by the FDA for use in the US. However, the control condition involved no stimulation, and blinding was not tested after one month, raising questions about a potential placebo effect.

This new UK clinical trial across two sites in London and Southampton tested TNS in a wider range of 150 children and adolescents diagnosed with ADHD aged between eight and 18 years old and applied a more rigorous placebo condition. Half of the sample received real TNS for about 9 hours every night for four weeks through battery-powered electrodes applied to the forehead. The other half of the sample received the ‘sham’ condition where electrodes were still applied to the forehead every night for four weeks but participants only received 30 seconds of stimulation every hour at a lower frequency and pulse width, which are thought to be non-effective and hence act as a “control” condition.

Professor Katya Rubia, Professor of Cognitive Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London and senior author of the study said: “Our study shows how important it is to design an appropriate placebo condition in clinical trials of brain therapies. There is a large placebo effect with high-tech brain therapies, in particular for patients and families that have an expectation that they can adjust brain differences associated with ADHD.  It is hence paramount to control for placebo effects in modern brain therapies to avoid false hopes.”

Dr Aldo Conti, postdoctoral researcher at IoPPN and at Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s College London and first author on the study said:  “This multicentre trial was designed to address key limitations of the previous pilot study that informed FDA clearance of TNS for ADHD, particularly by using a rigorously controlled sham condition that supported successful blinding across the treatment period. Unlike the earlier study, which was limited to younger children, we also included adolescents, a clinically important group given well-documented challenges with long-term medication adherence. These design choices enabled a more robust and clinically relevant evaluation of TNS.”

By comparing the groups researchers evaluated effectiveness of TNS by assessing the symptoms of ADHD as reported by parents, alongside other outcomes such as mind-wandering and attention, depression and anxiety, and sleep.

The trial showed that TNS was safe with no serious adverse events and most participants considered it a mild or no burden to use. However, the results showed no significant change in ADHD symptoms, objective measures of hyperactivity, attention and associated behaviours around mood and sleep.

Professor Samuele Cortese, NIHR Research Professor at University of Southampton and study lead for the Southampton site, stated: “Rigorous evidence, such as that generated by this study, is essential for supporting shared decision-making regarding interventions for ADHD. It empowers individuals with ADHD and their families to make informed choices about the treatment of ADHD. Clinicians, individuals with ADHD, and their families need to know which treatments work, and which do not based on the best evidence.”

The trial was run by the King’s Clinical Trials Unit and recruitment involved the Child and Adolescent Mental Health Services (CAMHS) clinics within the following NHS trusts: South London and Maudsley NHS Foundation Trust, Hampshire and Isle of Wight Healthcare (previously known as SOLENT NHS Trust), Central and North-West London NHS Foundation Trust, Oxleas NHS Foundation Trust and South-West London and St. George’s Mental Health NHS Trust.

External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial by Conti, A.A. et al. is published in Nature Medicine. https://doi.org/10.1038/s41591-025-04075-x

END

ELSE PRESS RELEASES FROM THIS DATE:

Scientists discover natural ‘brake’ that could stop harmful inflammation

2026-01-16

Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation – a breakthrough that could lead to new treatments for chronic diseases affecting millions worldwide. Inflammation is the body’s frontline defence against infection and injury, but when it doesn’t switch off properly, it can drive serious health conditions such as arthritis, heart disease, and diabetes. Until now, scientists didn’t fully understand how the body decides to stop the immune ‘fight’ response and start healing. Published in Nature Communications, the study reveals that tiny fat-derived molecules ...

Tougher solid electrolyte advances long-sought lithium metal batteries

2026-01-16

A solid – rather than liquid – electrolyte between the opposite electrodes of a battery should, in theory, enable a rechargeable lithium metal battery that is safer, packs much more energy, and charges considerably faster than the lithium-ion batteries commercially available today. For decades, scientists and engineers have explored several paths to realize the great promise of lithium metal batteries. A major problem with the solid, crystalline electrolytes under study has been the formation of microscopic cracks that ...

Experts provide policy roadmap to reduce dementia risk

2026-01-16

A national panel of experts has issued the strongest call yet for the Department of Health and Social Care to overhaul how it approaches dementia prevention, pointing to vital evidence that dementia risk can be reduced and providing a framework for the development of new government policy that could improve brain health for millions. The Nottingham Consensus, published in Nature Reviews Neurology, was led by researchers at the NIHR Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University ...

New 3D imaging system could address limitations of MRI, CT and ultrasound

2026-01-16

In a proof-of-concept study funded by the National Institutes of Health, researchers from the Keck School of Medicine of USC and the California Institute of Technology (Caltech) have shown that an innovative, noninvasive technique can be used to quickly collect 3D images of the human body, from head to foot. The technology combines ultrasound and photoacoustic imaging, which detects sound waves generated by light, to simultaneously collect images of both tissue and blood vessels. The findings, just published in the journal Nature Biomedical Engineering, have the potential to address current gaps in medical imaging. Imaging ...

First-in-human drug trial lowers high blood fats

2026-01-16

When we eat, our bodies convert extra calories, especially from carbs, sugar, fats, and alcohol, into molecules called “triglycerides”. Triglycerides are a form of fat or “lipid”, which the body stores away into its fat cells as an energy fuel for energy between meals. But, as we all know, excess amounts of fat in the body can be dangerous, causing a condition known as “hypertriglyceridemia” (“excess triglycerides in the blood”), which significantly increases the risk of heart disease, stroke, and pancreatitis. This ...

Decades of dredging are pushing the Dutch Western Scheldt Estuary beyond its ecological limits

2026-01-16

The Dutch Western Scheldt Estuary has been pushed onto an unsustainable trajectory since large-scale navigation channel deepening began in the 1970s. The dramatic increase in the annual volume of dredged sediment from the navigation channel has reduced feeding grounds for birds and made the estuary more vulnerable to sea-level rise. This is shown by the Dutch report De Westerscheldenatuur: Een mooie toekomst vraagt keuzes nu!. Dutch and Flemish researchers call on policymakers to use dredged sediment strategically for nature restoration and climate adaptation. After analysing nearly seventy years of monitoring data from the Dutch water ...

A view into the innermost workings of life: First scanning electron microscope with nanomanipulator inaugurated in hesse at Goethe University

2026-01-16

FRANKFURT. With a so-called cryo plasma-FIB (Plasma Focused Ion Beam) scanning electron microscope with nanomanipulator, the Goethe University in Frankfurt (Germany) is expanding its research infrastructure with a powerful instrument. The microscope was inaugurated today at the Buchmann Institute for Molecular Life Sciences on the Riedberg Campus – as the first of its kind in Hesse and one of only a few in all of Germany. The large-scale instrument works with a focused plasma ion beam, which can be used to prepare tiny sections from biological cells – so-called nanobiopsies with dimensions in the nanometer range. The decisive advantage ...

Simple method can enable early detection and prevention of chronic kidney disease

2026-01-16

Subtle abnormalities in kidney function – even within the range considered normal – may help identify people at risk of developing chronic kidney disease. This is shown in a new study from Karolinska Institutet, published in Kidney International. The researchers have therefore developed a web-based tool that could aid in early detection and thus primary prevention. Chronic kidney disease is a growing global health concern afflicting 10−15 per cent of adults worldwide and is projected ...

S-species-stimulated deep reconstruction of ultra-homogeneous CuS nanosheets for efficient HMF electrooxidation

2026-01-16

RESEARCH The massive consumption of fossil fuels in human society has led to increasingly severe resource crises and environmental pollution, and the efficient utilization of renewable biomass resources is one of the feasible approaches to addressing these issues. The electrocatalytic oxidation of 5-hydroxymethylfurfural (HMF) to produce 2,5-furandicarboxylic acid (FDCA) is expected to reduce the excessive reliance on fossil resource-derived terephthalic acid (PTA), a petroleum-based platform molecule. However, the development of high-performance and low-cost electrocatalysts for the efficient HMF oxidation ...

Mechanical and corrosion behavior of additively manufactured NiTi shape memory alloys

2026-01-16

A team from Lanzhou University of Technology have developed a novel NiTi shape memory allow (SMA) with harmonic microstructures fabricated via selective laser melting (SLM). This work explores the relationship between microstructural evolution at various deformation stages and corrosion behaviour in seawater environments. The study reveals that in its initial states, the alloy exhibits superior corrosion resistance, primarily owing to dense and stable passivation films composed mainly of TiO₂ and NiO. Post-fracture, the formation of fragmented amorphous phases and nanocrystalline grains accelerates corrosion processes. Leveraging first-principles ...

LAST 30 PRESS RELEASES: